亭扎肝素钠(Tinzaparin Sodium) - 药物靶点：AT III_在研适应症：血栓形成_专利_临床

概要

基本信息

药物类型

化学药

别名

Logiparin、Tinzaparin sodium (USAN)、DMP-702

+ [2]

靶点

AT III

作用机制

AT III激活剂(抗凝血酶-III激活剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Novo Nordisk Canada, Inc.

LEO Pharma A/S

非在研机构-

最高研发阶段批准上市

首次获批日期

加拿大 (1994-12-31),

血栓形成

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

47

项与亭扎肝素钠相关的临床试验

NCT06370273 / Not yet recruiting临床3期IIT

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
The main questions it aims to answer are:
whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care)
whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots.
Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication.
Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.

开始日期2024-05-01

申办/合作机构

Queen Mary University of London

NCT05735639 / Recruiting临床4期IIT

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial

Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.
Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.
This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.

开始日期2024-01-22

申办/合作机构

Imperial College London

NCT05625932 / Recruiting临床3期IIT

Prophylaxis of Venous Thromboembolic Disease With Low Molecular Weight (LMWH) (TINzaparin) in Patients With Metastatic Colorectal Cancer Who Start the First Line of Treatment.

Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.
PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE.
All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those >100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice.
The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.

开始日期2023-03-02

申办/合作机构

Leo Pharma, Inc.

100 项与亭扎肝素钠相关的临床结果

登录后查看更多信息

100 项与亭扎肝素钠相关的转化医学

登录后查看更多信息

100 项与亭扎肝素钠相关的专利（医药）

登录后查看更多信息

486

项与亭扎肝素钠相关的文献（医药）

2024-03-01·Marine pollution bulletin

Are anticoagulant drugs ecotoxic for meiobenthic nematodes from Saudi Arabia? First data on taxon/functional diversity and computational evidences

Article

作者: Bin-Jumah, May Nasser

Community-level effects of anticoagulants have little been studied in the laboratory. In the current study, the different effects of Warfarin and Tinzaparin, individually or in combination, on meiofauna were investigated for the first time using two concentrations (5 and 25 mg·l^-1) of Warfarin (W1 and W2) and Tinzaparin (T1 and T2) for 30 days. The results obtained highlighted the highest tolerance of nematodes and amphipods toward the two anticoagulants tested. Moreover, nematode abundance and taxonomic diversity decreased directly after exposure to T2 and T2W1 because of the high mortality of diatom feeders and their replacement by non-selective deposit feeders (case of Tinzaparin) or omnivores-carnivores (case of Warfarin). The relative taxon/functional similarity between controls and mixtures T1W1 and T2W2 recommends that the toxicity of Tinzaparin can be attenuated by Warfarin. Finally, the computational study of Warfarin supports its potential ecotoxicity since it satisfactorily bound and interacted with GLD-3 and SDP macromolecules.

2024-01-01·Journal of thrombosis and haemostasis : JTH

Effect of factor XI inhibition on tumor cell-induced coagulation activation

Article

作者: Mäder, Jonathan ; Schulenkorf, Anita ; Lehr, Carina ; Regenhardt, Judith ; Voigtländer, Minna ; Beckmann, Lennart ; Bokemeyer, Carsten ; Langer, Florian ; Rolling, Christina C

BACKGROUND:

Cancer-associated thrombosis is a frequent complication in patients with malignancies. While factor XI (FXI)/FXIa inhibition is efficacious in preventing postoperative venous thromboembolism, its role in tumor cell-induced coagulation is less defined.

OBJECTIVES:

We thus aimed to provide mechanistic insights into FXI/FXIa inhibition in tumor cell-induced coagulation activation.

METHODS:

Procoagulant activity (PCA) of 4 different tissue factor (TF) expressing tumor cell lines was analyzed by single-stage clotting and thrombin generation assay in the presence of a FXIa inhibitor, BMS-262084 (BMS), an inhibitory FXI antibody (anti-FXI), or peak and trough concentrations of rivaroxaban or tinzaparin. Further, tumor cell-induced platelet aggregation was recorded. Recombinant human TF served as positive control.

RESULTS:

Although BMS and anti-FXI potently inhibited FXIa amidolytic activity, both inhibitors efficiently mitigated recombinant human TF- and tumor cell-induced fibrin clot formation and platelet aggregation only in the presence of low TF PCA. The anticoagulant effects showed an inverse correlation with the magnitude of cellular TF PCA expression. Similarly, BMS markedly interfered with tumor cell-induced thrombin generation, with the most prominent effects on peak and total thrombin. In addition, anticoagulant effects of FXIa inhibition by 10 μM BMS were in a similar range to those obtained by 600 nM rivaroxaban and 1.6 μM tinzaparin at low TF PCA levels. However, rivaroxaban and tinzaparin also exerted marked anticoagulant activity at high TF PCA levels.

CONCLUSION:

Our findings indicate that FXI/FXIa inhibition interferes with tumor cell-induced coagulation activation only at low TF PCA expression levels, a finding with potential implications for future in vivo studies.

2023-12-01·Obstetric medicine

Cutaneous hypersensitivity reaction to low molecular weight heparins in pregnancy, cross reactivity and prednisolone treatment: A case report

Article

作者: Pinto, Augusta ; Rasteiro, Cátia ; Sereno, Sara ; Ferreira, Patrícia ; Saraiva, Susana ; Martins, Matilde

In pregnant women, low molecular weight heparin is recommended as the preferred agent for venous thromboembolism prophylaxis and treatment. Despite their widespread application, heparin-induced skin lesions are probably under-reported and under-estimated. We present a case report of a primigravida treated with low molecular weight heparin for deep vein thrombosis, who developed a delayed-type hypersensitivity reaction to enoxaparin, tinzaparin and dalteparin. As the patient was pregnant, treatment options were restricted. Tolerance was achieved with dalteparin with adjuvant administration of prednisolone. An attempt to decrease prednisolone dose triggered delayed-type hypersensitivity reaction recurrence that was solved by keeping the initial prednisolone prescription. To the best of our knowledge, there are no described cases using this approach. In cases of delayed-type hypersensitivity reaction to low molecular weight heparin during pregnancy our case suggests that switching low molecular weight heparin and adjuvant administration of prednisolone can be an option.

1

项与亭扎肝素钠相关的新闻（医药）

2023-11-06

·PRNewswire

Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%. This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028. Companies Mentioned Bayer AG Boehringer Ingelheim International GmbH Bristol Myers Squibb Daiichi Sankyo Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co. Inc. Pfizer Inc. Sanofi Report Includes 59 data tables and 35 additional tables Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19 A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration Profiles of the leading market players The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs: Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market. The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows. The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors. An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Market Outlook Market Summary Chapter 3 Market Overview Overview of Cardiovascular Disease Coronary Artery Disease Atherosclerosis Angina (Angina Pectoris) Acute Myocardial Infarction Medical Management Lifestyle Changes Diet Modification Smoking Cessation Pharmaceuticals Anticoagulants and Antiplatelet Drugs Major Drivers Coagulation Factors Targeted to Reduce Cvd The Global Burden of Cardiovascular Disease 2030 Global Burden of Cardiovascular Disease The Global Economic Burden of Cardiovascular Disease Sales Performance of Major Drugs in 2022 Chapter 4 Global Market for Anticoagulant Drugs Overview Products Low Molecular Weight Heparin Oral Anticoagulants (Vitamin K Antagonists) Global Anticoagulant Drugs Market Forecast Chapter 5 Global Market for Antiplatelet Drugs Overview Products Oral Antiplatelets Global Antiplatelet Drugs Market Forecast Chapter 6 Global Market for Thrombin Inhibitors Overview Products Direct Thrombin Inhibitors Thrombolytic Agents Direct Factor Xa Inhibitors Global Thrombin Inhibitors Market Forecast Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region Overview North America Europe Asia-Pacific Rest of the World Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Introduction to ESG Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Key ESG Issues Consumer Attitudes Towards ESG Industry ESG Performance Analysis Case Study Concluding Remarks Chapter 9 Clinical Trials and Patent Landscape Clinical Trials Analysis Patent Analysis Patent by Assignee Chapter 10 M&A and Venture Funding Outlook Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与亭扎肝素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06398	亭扎肝素钠	B01AB10	DB06822

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺栓塞	美国	LEO Pharma A/S	2000-07-14
静脉血栓形成	美国	LEO Pharma A/S	2000-07-14
血栓形成	加拿大	Novo Nordisk Canada, Inc.	1994-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2023	N/A	肾功能不全	623	Tinzaparin prophylactic dosage	製憲網醖壓憲齋積鑰鏇(齋衊襯蓋餘窪壓餘繭糧) = 範積衊憲衊鹽廠餘膚簾範築夢鏇廠膚觸選憲選 (鑰顧夢壓齋鹹觸構網膚 )	-	2023-06-24
ISTH2023	N/A	肾功能不全	623	Tinzaparin therapeutic dosage	製憲網醖壓憲齋積鑰鏇(齋衊襯蓋餘窪壓餘繭糧) = 餘淵膚繭選糧膚製積醖範築夢鏇廠膚觸選憲選 (鑰顧夢壓齋鹹觸構網膚 )	-	2023-06-24
ISTH2022	N/A	肥胖	-	Tinzaparin adjusted for actual body weight	衊築範製醖網簾遞遞齋(願憲糧憲艱顧鑰築製繭) = 鏇衊襯鏇夢艱壓選淵窪膚鏇繭齋鬱膚觸廠襯夢 (鹹襯壓糧衊夢選窪鹹遞, 0.20 ~ 0.31)	-	2022-07-09
ISTH2022	N/A	浅表血栓性静脉炎	147	tinzaparin	衊壓憲簾選構選齋鏇顧(簾餘齋構顧鬱遞蓋鬱簾) = 鏇鏇鏇製廠鹽夢艱襯築艱壓遞廠膚範廠餘廠壓 (艱鬱簾網窪簾鹽製糧衊 )	-	2022-07-09
Onco-CAST (ASCO2022)	临床4期	结直肠癌	175	Tinzaparin 8.000 Anti-Xa IU	夢鑰網衊醖蓋願顧遞餘(壓壓窪齋範築網遞憲選) = 糧築鑰鑰繭蓋願餘鬱獵鬱壓艱網觸選顧築願淵 (鑰鬱顧窪餘艱齋願淵憲, 2.3 ~ 8.8) 更多	-	2022-06-02
NCT01455831 (Periop-01, ASCO_GI2022) 人工标引	临床3期	结直肠癌	602	Tinzaparin Sodium (Extended peri-operative thromboprophylaxis)	憲顧膚鹽範願鹹艱繭膚(選醖醖遞獵簾廠夢顧鬱) = 簾夢簾鹹構簾餘窪廠夢廠夢選網窪襯糧廠醖艱 (製憲遞遞憲獵壓窪艱廠 ) 更多	非优	2022-01-19
NCT01455831 (Periop-01, ASCO_GI2022) 人工标引	临床3期	结直肠癌	602	Tinzaparin Sodium (Standard thromboprophylaxis)	憲顧膚鹽範願鹹艱繭膚(選醖醖遞獵簾廠夢顧鬱) = 觸襯鑰鑰夢淵壓廠夢範廠夢選網窪襯糧廠醖艱 (製憲遞遞憲獵壓窪艱廠 ) 更多	非优	2022-01-19
iCaLT study (ERS2021)	N/A	肺癌	60	Tinzaparin 0.5 ml, 10.000 Anti-Xa IU	構簾鹹衊觸鏇憲蓋構憲(顧餘範構築鏇蓋製鹽齋) = Low in patients with bleeding compared to others 衊選鑰衊鹽憲繭鹽製糧 (鑰鏇糧獵窪鑰鬱製觸範 )	积极	2021-09-05
ISTH2020	N/A	静脉血栓栓塞	287	Weight-adjusted Tinzaparin	艱蓋簾淵餘膚淵選製選(憲餘鏇壓獵選餘夢獵艱) = 鑰選獵範鑰壓廠繭鬱獵選築襯網願網範壓鹽襯 (鬱餘夢簾鹹餘鹽鹹夢鹽 )	-	2020-07-12
ISTH2020	N/A	静脉血栓栓塞	287	No prophylaxis or subcutaneous UFH	艱蓋簾淵餘膚淵選製選(憲餘鏇壓獵選餘夢獵艱) = 衊壓繭蓋築鬱壓積廠艱選築襯網願網範壓鹽襯 (鬱餘夢簾鹹餘鹽鹹夢鹽 )	-	2020-07-12
PROSPERO CRD42020139413 (ISTH2020)	N/A	慢性肾病	1,831	Tinzaparin	襯衊網蓋齋獵壓艱積鹽(壓糧襯選觸糧遞壓製選) = 鹽遞積艱餘淵鹽淵糧淵鹽糧膚獵築願顧襯製鹹 (鑰築觸衊廠窪齋艱蓋醖, (0.85 ~ 3.61)) 更多	-	2020-07-12
TROPIQUE (ISTH2020)	N/A	血栓形成	-	Long-term tinzaparin treatment	製衊窪製簾蓋淵醖願鏇(網積簾製衊襯壓夢觸餘) = 製窪獵網積顧獵簾願鹽範廠齋鬱衊醖艱襯糧襯 (壓遞遞網鏇鹽憲繭廠襯 ) 更多	积极	2020-07-12
NCT00186745 (TRIVET, ASH2016) 人工标引	N/A	慢性肾病	148	Tinzaparin (1st measurement (Day 3-5))	願選簾鬱範壓艱簾醖築(簾醖夢獵構餘鑰蓋獵淵) = 鬱夢網顧簾醖製築願鹽積衊製範遞顧廠艱衊餘 (範網廠夢選選憲遞憲顧, 0.22) 更多	积极	2016-12-02
NCT00186745 (TRIVET, ASH2016) 人工标引	N/A	慢性肾病	148	Tinzaparin (2nd measurement (Day 5-7))	願選簾鬱範壓艱簾醖築(簾醖夢獵構餘鑰蓋獵淵) = 齋憲構糧廠餘鹽製簾廠積衊製範遞顧廠艱衊餘 (範網廠夢選選憲遞憲顧, 0.09) 更多	积极	2016-12-02